---
title: 'Immunotherapeutic approaches for systemic lupus erythematosus: early overview
  and future potential'
date: '2024-01-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38282801/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240129170656&v=2.18.0
source: heidelberg[Affiliation]
description: Systemic lupus erythematosus (SLE) is a complex autoimmune disease. Current
  SLE therapies include immunosuppressants, antimalarial drugs, non-steroidal anti-inflammatory
  drugs (NSAIDs), and corticosteroids, but these treatments can cause substantial
  toxicities to organs and may not be effective for all patients. In recent years,
  significant progress has been made in the treatment of SLE using immunotherapy,
  including Benlysta and Saphnelo. These advances in immunotherapy hold promise for
  ...
disable_comments: true
---
Systemic lupus erythematosus (SLE) is a complex autoimmune disease. Current SLE therapies include immunosuppressants, antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids, but these treatments can cause substantial toxicities to organs and may not be effective for all patients. In recent years, significant progress has been made in the treatment of SLE using immunotherapy, including Benlysta and Saphnelo. These advances in immunotherapy hold promise for ...